Duration of treatment – emergent adverse events

Phase 2/3 trials in Xydalba clinical trial programme

Graph showing the Duration of Treatment - Emergent Adverse Events

The median duration of adverse events11:

  • Xydalba 3 days
  • Comparator 4 days
11 Dunne MW et al. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Safety. 2015